Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2022-02-02 00:00:00 ET · period of report 2022-01-31 · accession 0001209191-22-006598 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-02 | 2022-01-31 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $2.48 | +15.6K | 57.3K | +37% | +$38.8K |
| D | 2022-02-02 | 2022-01-31 | RXRX | Doyle Ramona | Chief Medical Off | M - OptEx | $0.00 | -15.6K | 694.1K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-01-31 | M | A | 15,625 | $2.48 | 57,335 | D | — | — | (F2) Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-31 | M | D | 15,625 | $0.00 | 694,053 | D | $2.48 · — to 2030-12-30 | 15,625 Class A Common Stock | (F3) Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. |